Evaluation of EGFR degradation as a mechanism of tumor evasion in EGFR-TKI resistant non-small cell lung cancer (NSCLC) cells compared to EGFR-TKI sensitive cells

被引：0
|
作者：
Norma, Hernandez-Pedro Y. [1 ]
Giovanny, Soca-Chafre [1 ]
Mario, Orozco-Morales [1 ]
Pedro, Barrios-Bernal [1 ]
Oscar, Arrieta [1 ]
机构：
[1] Inst Nacl Cancerol, Mexico City, DF, Mexico
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-186
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-186
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.
    Liang, Li
    Li, Fang
    Cao, Baoshan
    Zhang, Zhaohui
    Zhu, Xiang
    Wang, Jiadong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [4] Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
    Grant, Christopher
    Nagasaka, Misako
    CANCER TREATMENT REVIEWS, 2024, 126
  • [5] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    Cancer Biology & Medicine, 2014, (04) : 270 - 276
  • [6] EGFR-TKI FOR LUNG CANCER
    Bai, Chunxue
    RESPIROLOGY, 2010, 15 : 23 - 23
  • [7] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
  • [8] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
    Guo-Hao Xia
    Yun Zeng
    Ying Fang
    Shao-Rong Yu
    Li Wang
    Mei-Qi Shi
    Wei-Li Sun
    Xin-En Huang
    Jia Chen
    Ji- Feng Feng
    Cancer Biology & Medicine, 2014, 11 (04) : 270 - 276
  • [9] Circulating Tumor Cells as a Risk Factor for Non-Small Cell Lung Cancer Treated with EGFR-TKI
    Liu, Yue
    Fan, Congying
    Hu, Haiyan
    Yang, Yaowen
    Yan, Shuning
    Gu, Yuelan
    Ding, Meng
    Li, Pengfei
    Wang, Yanling
    Wang, Hongyan
    Yang, Qie
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2022, 18 (02) : 199 - 206
  • [10] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
12345